GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase III
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Zacks.com on MSN3d
Gilead, MRK Report Data From Investigational Combination Study for HIV
Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
Fred Hutch3d
Infectious disease experts propose trials network dedicated to immunocompromised patients
On September 10, experts across disciplines, from infectious disease clinicians to regulators to representatives from the pharmaceutical industry, convened at the inaugural ImmunOptimize workshop in ...
Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...
Business Wire4d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Medscape7d
HIV-Positive Donors Safe for Kidney Transplants
The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...
healthday8d
Kidney Transplants Safe When Donor, Recipient Both HIV-Positive
People living with HIV who need a kidney can rest assured that outcomes are similar whether their kidney donor was ...
The American Journal of Managed Care8d
Financial Burdens of HIV Treatment and HCRU
Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...
Truepill’s Sid Viswanathan Is Back With A New Pharmacy Startup Focused On HIV
Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...
Business Wire15d
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
The data from 31 presentations across HIV treatment and prevention ... in combination with an optimized background regimen in people with multi-drug resistant HIV. HIV prevention data will ...
WebMD18d
Apretude for HIV Pre-Exposure Prevention (PrEP)
How Was It Studied for the Prevention of HIV? Two large studies were conducted to see if Apretude is safe and effective as a PrEP regimen in ... you can tolerate the medication.